To provide more definitive data on whether T-type inhibition is useful in treating Dravet syndrome, a future study could assess the effects of selective T-type calcium channel inhibitors with improved oral pharmacokinetic properties in the Scn1a+/− mice. This evidence concerns the gene SCN1A and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.